Sector News

Brazil’s largest pharma leads race for Takeda’s $1B Latin American business: report

May 20, 2019
Life sciences

Binding offers could soon come in for Takeda’s Latin American business, which could fetch the company $1 billion to help pay off debt. And Brazil’s largest drugmaker is reportedly in the lead.

EMS Pharma is now the front-runner to make a formal proposal by the end of May, Reuters reported, citing three sources with knowledge of the process.

Blackstone-backed Brazilian investment shop Patria Investments could also come up with an offer, while other previously rumored potential bidders such as private equity firms and frequent pharma buyers Advent and CVC Capital Partners may not be interested in the unit after their analyses, the sources told the news service.

A fourth source told Reuters that EMS is very interested in the franchise. It’s not a total surprise, given that its sister company Novamed last year picked up Takeda’s Brazil-based, wholly owned unit Multilab for 500 million Brazilian real ($130 million). Both EMS and Novamed belong to Brazilian holding company NC Group under its pharmaceutical umbrella.

In the 2018 fiscal year that ended in March, Takeda recorded sales in Latin America of 88.1 billion Japanese yen ($800 million), up from 75.7 billion yen in the previous fiscal cycle. But make no mistake—the jump can largely be attributed to the addition of three months’ worth of Shire revenue, as Takeda wrapped the Shire megamerger in January. If looking only at the pre-Shire nine months, the business’ revenue dropped by 2.8% year over year.

Latin America constitutes about 4% of Takeda’s total revenue, and the unit sells prescription drugs in oncology and gastroenterology as well as vaccines and some over-the-counter products.

During Takeda’s full-year earnings call this month, CEO Christophe Weber restated that his company is looking to jettison $10 billion worth of assets to help bring down its debt level to 2.0x adjusted EBITDA in three to five years.

Toward that goal, it has agreed to sell its Xiidra eye drops to Novartis for up to $5.3 billion and its TachoSil surgical patch to Johnson & Johnson for about $400 million. Other selloffs will come from “hundreds of products” outside of its core areas of gastrointestinal, rare diseases, plasma therapies, oncology and neuroscience, Weber said.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).